January 15, 2022

Dermavant Presents New Patient Satisfaction Data f ...

Read More

January 7, 2022

Dermavant to Present New Data from Phase 3 PSOARIN ...

Read More

December 9, 2021

Dermavant Announces Publication of PSOARING 1  ...

Read More

December 9, 2021

The New England Journal of Medicine: Phase 3 Trial ...

Read More

September 30, 2021

Dermavant Showcases New Long-Term Data from Phase ...

Read More

September 23, 2021

Dermavant to Present New Data on Phase 3 PSOARING ...

Read More

September 9, 2021

Dermavant Announces First Patient Dosed in ADORING ...

Read More

August 10, 2021

Dermavant Announces FDA Acceptance for Filing of N ...

Read More

June 7, 2021

Dermavant Announces $200 Million of Financing ...

Read More

June 3, 2021

Dermavant Submits New Drug Application (NDA) to FD ...

Read More

May 6, 2021

Dermavant Announces Appointment of Michael Swartzb ...

Read More

April 16, 2021

Dermavant Announces Tapinarof Data Presentations a ...

Read More

March 25, 2021

FORTUNE Names Dermavant One of the 2021 Best Workp ...

Read More

March 11, 2021

Dermavant Announces Tapinarof Data Presentation at ...

Read More

February 18, 2021

Positive Data from PSOARING 3 Support Long-Term Us ...

Read More

January 21, 2021

Dermavant Announces Tapinarof Data Presentation at ...

Read More

November 17, 2020

Dermavant Named One of Fortune® Magazine’s 2020 ...

Read More

October 27, 2020

Dermavant’s Pivotal Phase 3 PSOARING Data for Ta ...

Read More

October 22, 2020

Dermavant Announces Presentation of Tapinarof Pivo ...

Read More

August 26, 2020

Dermavant Reports Positive Phase 3 Results for Tap ...

Read More